Aktas O - Search Results

1

Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension.

Albrecht P, Blasberg C, Ringelstein M, Müller AK, Finis D, Guthoff R, Kadas EM, Lagreze W, Aktas O, Hartung HP, Paul F, Brandt AU, Methner A. Albrecht P, et al. Among authors: aktas o. J Neurol. 2017 Jul;264(7):1370-1380. doi: 10.1007/s00415-017-8532-x. Epub 2017 Jun 5. J Neurol. 2017. PMID: 28584914

2

Revised diagnostic criteria for neuromyelitis optica--incorporation of NMO-IgG status.

Jarius S, Paul F, Franciotta D, Aktas O, Hohlfeld R, Zipp F, Vincent A. Jarius S, et al. Among authors: aktas o. Nat Clin Pract Neurol. 2007 May;3(5):E1. doi: 10.1038/ncpneuro0501. Nat Clin Pract Neurol. 2007. PMID: 17479069 No abstract available.

3

Impact of HMG-CoA reductase inhibition on brain pathology.

Zipp F, Waiczies S, Aktas O, Neuhaus O, Hemmer B, Schraven B, Nitsch R, Hartung HP. Zipp F, et al. Among authors: aktas o. Trends Pharmacol Sci. 2007 Jul;28(7):342-9. doi: 10.1016/j.tips.2007.05.001. Epub 2007 Jun 15. Trends Pharmacol Sci. 2007. PMID: 17573124 Review.

4

Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis.

Paul F, Waiczies S, Wuerfel J, Bellmann-Strobl J, Dörr J, Waiczies H, Haertle M, Wernecke KD, Volk HD, Aktas O, Zipp F. Paul F, et al. Among authors: aktas o. PLoS One. 2008 Apr 9;3(4):e1928. doi: 10.1371/journal.pone.0001928. PLoS One. 2008. PMID: 18398457 Free PMC article. Clinical Trial.

5

Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases.

Aktas O, Hartung HP. Aktas O, et al. J Neurol. 2009 Nov;256(11):1906-8. doi: 10.1007/s00415-009-5317-x. J Neurol. 2009. PMID: 19768482 No abstract available.

6

Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis.

Vogt J, Paul F, Aktas O, Müller-Wielsch K, Dörr J, Dörr S, Bharathi BS, Glumm R, Schmitz C, Steinbusch H, Raine CS, Tsokos M, Nitsch R, Zipp F. Vogt J, et al. Among authors: aktas o. Ann Neurol. 2009 Sep;66(3):310-22. doi: 10.1002/ana.21719. Ann Neurol. 2009. PMID: 19798635

7

Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope.

Hartung HP, Aktas O. Hartung HP, et al. Among authors: aktas o. Ann Neurol. 2009 Oct;66(4):429-32. doi: 10.1002/ana.21880. Ann Neurol. 2009. PMID: 19847907 No abstract available.

8

Development of oral cladribine for the treatment of multiple sclerosis.

Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC. Hartung HP, et al. Among authors: aktas o. J Neurol. 2010 Feb;257(2):163-70. doi: 10.1007/s00415-009-5359-0. J Neurol. 2010. PMID: 19921304 Review.

9

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.

Aktas O, Kieseier B, Hartung HP. Aktas O, et al. Trends Neurosci. 2010 Mar;33(3):140-52. doi: 10.1016/j.tins.2009.12.002. Epub 2010 Jan 4. Trends Neurosci. 2010. PMID: 20045200 Review.

10

Oral therapies for multiple sclerosis: are we there yet?

Hartung HP, Aktas O. Hartung HP, et al. Among authors: aktas o. Lancet Neurol. 2010 May;9(5):454-7. doi: 10.1016/S1474-4422(10)70088-0. Lancet Neurol. 2010. PMID: 20398852 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

429 results

Search Page

Filters